vs
Orthofix Medical Inc.（OFIX）与Oportun Financial Corp（OPRT）财务数据对比。点击上方公司名可切换其他公司
Oportun Financial Corp的季度营收约是Orthofix Medical Inc.的1.1倍（$247.7M vs $219.9M），Oportun Financial Corp净利率更高（1.4% vs -1.0%，领先2.4%），Orthofix Medical Inc.同比增速更快（2.0% vs -1.3%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -0.5%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Oportun Financial Corp是总部位于美国的金融科技公司，专注为信用记录有限或无信用记录的中低收入弱势消费群体提供个人贷款、信用卡、储蓄产品等可负担的金融服务，依托自研AI风控模型保障服务公平性与风险可控。
OFIX vs OPRT — 直观对比
营收规模更大
OPRT
是对方的1.1倍
$219.9M
营收增速更快
OFIX
高出3.2%
-1.3%
净利率更高
OPRT
高出2.4%
-1.0%
两年增速更快
OFIX
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $247.7M |
| 净利润 | $-2.2M | $3.4M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 2.6% |
| 净利率 | -1.0% | 1.4% |
| 营收同比 | 2.0% | -1.3% |
| 净利润同比 | 92.4% | -61.0% |
| 每股收益（稀释后） | $-0.05 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXOPRT
| Q4 25 | $219.9M | $247.7M | ||
| Q3 25 | $205.6M | $238.7M | ||
| Q2 25 | $203.1M | $234.3M | ||
| Q1 25 | $193.6M | $235.9M | ||
| Q4 24 | $215.7M | $250.9M | ||
| Q3 24 | $196.6M | $250.0M | ||
| Q2 24 | $198.6M | $250.4M | ||
| Q1 24 | $188.6M | $250.5M |
净利润OFIXOPRT
| Q4 25 | $-2.2M | $3.4M | ||
| Q3 25 | $-22.8M | $5.2M | ||
| Q2 25 | $-14.1M | $6.9M | ||
| Q1 25 | $-53.1M | $9.8M | ||
| Q4 24 | $-29.1M | $8.7M | ||
| Q3 24 | $-27.4M | $-30.0M | ||
| Q2 24 | $-33.4M | $-31.0M | ||
| Q1 24 | $-36.0M | $-26.4M |
毛利率OFIXOPRT
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXOPRT
| Q4 25 | 0.2% | 2.6% | ||
| Q3 25 | -8.3% | 6.0% | ||
| Q2 25 | -7.9% | 4.3% | ||
| Q1 25 | -25.2% | 5.6% | ||
| Q4 24 | -5.3% | 89.6% | ||
| Q3 24 | -9.6% | -15.8% | ||
| Q2 24 | -12.5% | -19.6% | ||
| Q1 24 | -15.6% | -12.2% |
净利率OFIXOPRT
| Q4 25 | -1.0% | 1.4% | ||
| Q3 25 | -11.1% | 2.2% | ||
| Q2 25 | -6.9% | 2.9% | ||
| Q1 25 | -27.4% | 4.1% | ||
| Q4 24 | -13.5% | 200.1% | ||
| Q3 24 | -13.9% | -12.0% | ||
| Q2 24 | -16.8% | -12.4% | ||
| Q1 24 | -19.1% | -10.6% |
每股收益（稀释后）OFIXOPRT
| Q4 25 | $-0.05 | $0.07 | ||
| Q3 25 | $-0.57 | $0.11 | ||
| Q2 25 | $-0.36 | $0.14 | ||
| Q1 25 | $-1.35 | $0.21 | ||
| Q4 24 | $-0.76 | $0.26 | ||
| Q3 24 | $-0.71 | $-0.75 | ||
| Q2 24 | $-0.88 | $-0.78 | ||
| Q1 24 | $-0.95 | $-0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $105.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $390.1M |
| 总资产 | $850.6M | $3.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXOPRT
| Q4 25 | $82.0M | $105.5M | ||
| Q3 25 | $62.9M | $104.6M | ||
| Q2 25 | $65.6M | $96.8M | ||
| Q1 25 | $58.0M | $78.5M | ||
| Q4 24 | $83.2M | $60.0M | ||
| Q3 24 | $30.1M | $71.8M | ||
| Q2 24 | $26.4M | $72.9M | ||
| Q1 24 | $27.0M | $69.2M |
总债务OFIXOPRT
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXOPRT
| Q4 25 | $450.0M | $390.1M | ||
| Q3 25 | $442.5M | $383.9M | ||
| Q2 25 | $458.3M | $376.0M | ||
| Q1 25 | $458.3M | $366.1M | ||
| Q4 24 | $503.1M | $353.8M | ||
| Q3 24 | $525.9M | $327.6M | ||
| Q2 24 | $546.0M | $354.1M | ||
| Q1 24 | $570.3M | $382.0M |
总资产OFIXOPRT
| Q4 25 | $850.6M | $3.3B | ||
| Q3 25 | $832.6M | $3.2B | ||
| Q2 25 | $837.2M | $3.2B | ||
| Q1 25 | $823.1M | $3.2B | ||
| Q4 24 | $893.3M | $3.2B | ||
| Q3 24 | $867.9M | $3.3B | ||
| Q2 24 | $882.0M | $3.3B | ||
| Q1 24 | $906.0M | $3.3B |
负债/权益比OFIXOPRT
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $413.4M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 121.45× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXOPRT
| Q4 25 | $27.7M | $413.4M | ||
| Q3 25 | $12.4M | $99.0M | ||
| Q2 25 | $11.6M | $104.5M | ||
| Q1 25 | $-18.4M | $101.0M | ||
| Q4 24 | $23.7M | $393.5M | ||
| Q3 24 | $11.7M | $108.5M | ||
| Q2 24 | $9.0M | $107.7M | ||
| Q1 24 | $-18.6M | $85.9M |
自由现金流OFIXOPRT
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXOPRT
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXOPRT
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXOPRT
| Q4 25 | — | 121.45× | ||
| Q3 25 | — | 19.05× | ||
| Q2 25 | — | 15.20× | ||
| Q1 25 | — | 10.34× | ||
| Q4 24 | — | 45.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
OPRT
暂无分部数据
